New drug combo aims to control Hard-to-Treat myeloma
NCT ID NCT05338775
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether combining two types of immune-boosting drugs (bispecific antibodies and a checkpoint inhibitor) is safe for people with multiple myeloma that has come back or stopped responding to treatment. About 74 participants will receive either talquetamab or teclistamab together with a PD-1 inhibitor. The main goal is to find safe doses and check for side effects, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Poitiers - Hopital la Miletrie
Poitiers, 86021, France
-
CHU de Montpellier Hopital Saint Eloi
Montpellier, 34295, France
-
CHU de Nantes hotel Dieu
Nantes, 44093, France
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp. Univ. Germans Trias I Pujol
Badalona, 08916, Spain
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, 31059, France
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
The Blavatnik Family Chelsea Medical Center at Mount Sinai
New York, New York, 10011, United States
-
Universitaetsklinikum Hamburg Eppendorf
Hamburg, 20246, Germany
-
Universitaetsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitatsklinikum Carl Gustav Carus Dresden
Dresden, 01307, Germany
-
Universitatsklinikum Wurzburg
Würzburg, 97080, Germany
-
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States